FOXK2抗体;FOXK2 Antibody—艾普蒂 新品

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-3: 231, A172 and HepG2 cell lysates, Primary antibody: P13619(FOXK2 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P13619(FOXK2 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P13619(FOXK2 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The FOXK2 antibody is a crucial tool in studying the FOXK2 protein, a member of the Forkhead box (FOX) family of transcription factors. FOXK2. encoded by the FOXK2 gene in humans, plays multifaceted roles in regulating gene expression linked to cell proliferation, metabolism, autophagy, and DNA damage response. Structurally, it contains a conserved Forkhead (FKH) domain for DNA binding and functional domains enabling interactions with chromatin modifiers like Sin3A/HDAC complexes. Research highlights its involvement in cancer progression, metabolic disorders, and neurological conditions, where it may act as either an oncogene or tumor suppressor depending on cellular context.

FOXK2 antibodies are widely used in techniques such as Western blotting, immunoprecipitation, and immunofluorescence to detect FOXK2 expression, localization, and protein interactions. These antibodies are typically developed in hosts like rabbits or mice using immunogenic peptides from conserved regions of FOXK2. Validation parameters include specificity tests (knockdown/knockout controls), cross-reactivity assessments across species (human, mouse, rat), and application-specific performance checks. Recent studies utilizing FOXK2 antibodies have uncovered its role in metabolic reprogramming of cancer cells and its interaction with mTOR signaling components. However, researchers must account for potential isoforms (e.g., FOXK2-iso1/iso2) and post-translational modifications that might affect antibody recognition. Commercial availability from multiple biotech vendors has accelerated research into FOXK2's therapeutic potential as a biomarker or drug target.